
CLAIM:

1. A compound of Formula (II):



(II)

wherein R^1 and R^2 independently are -C(=O)R^3 and R^3 is selected from the group consisting of isopropyl, 3-pentyl, cyclopentyl, phenyl, and phenylmethyl.


2. An aqueous parenteral suspension comprising a compound of claim 1;

a non-ionic surfactant;

a suspending agent; and water.


3. The aqueous parenteral suspension of claim 2, wherein said compound is present in an amount in the range of 3 to 4.5 percent by weight of the suspension, said non-ionic surfactant is present in an amount in the range of 0.1 to 0.5 percent by weight of the suspension, and said suspending agent is present in an amount in the range of 0.1 to 0.5 weight percent by weight of the suspension.

4. The aqueous suspension of claim 2 or 3, wherein the compound is:




.

5. The aqueous suspension of claim 2 or 3, wherein the compound is:



.

6. The aqueous suspension of claim 2 or 3, wherein the compound is:



.

7. The aqueous parenteral suspension of any one of claims 2 to 6, wherein the non-ionic surfactant is polyoxyethylene (20) sorbitan monooleate.


8. The aqueous parenteral suspension of any one of claims 2 to 7, wherein the suspending agent is selected from the group consisting of methyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, and hydroxypropylmethyl cellulose.

9. Use of the compound of claim 1, or the suspension of any one of claims 2 to 8, in the preparation of a medicament for *in vivo* suppression of a human immunodeficiency virus (HIV) or Hepatitis B virus (HBV) virus in a patient.

10. Use of the compound of claim 1, or the suspension of any one of claims 2 to 8, for the preparation of a medicament for prophylaxis of a human immunodeficiency virus (HIV) or Hepatitis B virus (HBV) infection in a human subject not infected with HIV or HBV.

11. Use of the compound of claim 1, or the suspension of any one of claims 2 to 8, for the preparation of a medicament for treating or preventing human immunodeficiency virus (HIV) infection in a human subject.

12. A crystalline form of the compound:




.

13. The crystalline form of claim 12, wherein the crystalline form is characterized by an XRPD pattern substantially as shown in Figure 4.

14. The crystalline form of claim 12 or 13, wherein the crystalline form is characterized by a DSC thermogram having an endothermic transition at 134.3 °C.


15. The crystalline form of any one of claims 12 to 14, wherein the crystalline form is characterized by a DSC thermogram substantially as shown in Figure 5.

16. A crystalline form of the compound:



.

17. A crystalline form of the compound:



.

18. The crystalline form of claim 17, wherein the crystalline form is characterized by an XRPD pattern substantially as shown in Figure 7.

19. The crystalline form of claim 17 or 18, wherein the crystalline form is characterized by a DSC thermogram having an endothermic transition at 158.9 °C.

20. The crystalline form of any one of claims 17 to 19, wherein the crystalline form is characterized by a DSC thermogram substantially as shown in Figure 8.